CRO Expands Clinical Capabilities, Accelerating Product Pipeline Development and Commercialization Opportunities
- Company Reports Sequential Revenue Growth of 12% Over Q4 2023 and Strong Gross Margins of 64% -
Enhanced Leadership, Revamped Sales Organization, Drive Improved Sales Efficiency and Customer Retention
After shutting their MIT lab, founders raise $11.1 million in first five months of company's inception